Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Md Hafiz Uddin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Exportin 1 Protein, Drug Combinations. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effective treatment strategy for this refractory disease. Previously, we have demonstrated that nuclear exporter protein exportin 1 (XPO1) is a valid therapeutic target in PDAC, and the selective inhibitor of nuclear export selinexor (Sel) synergistically enhances the efficacy of GemPac in pancreatic cancer cells, spheroids and patient‐derived tumours, and had promising activity in a phase I study.
Methods
Here, we investigated the impact of selinexor–gemcitabine–nab‐paclitaxel (Sel‐GemPac) combination on LSL‐Kras G12D/+ ; LSL‐Trp53 R172H/+ ; Pdx1‐Cre (KPC) mouse model utilising digital spatial profiling (DSP) and single nuclear RNA sequencing (snRNAseq).
Results
Sel‐GemPac synergistically inhibited the growth of the KPC tumour‐derived cell line. The Sel‐GemPac combination reduced the 2D colony formation and 3D spheroid formation. In the KPC mouse model, at a sub‐maximum tolerated dose (sub‐MTD) , Sel‐GemPac enhanced the survival of treated mice compared to controls ( p < .05). Immunohistochemical analysis of residual KPC tumours showed re‐organisation of tumour stromal architecture, suppression of proliferation and nuclear retention of tumour suppressors, such as Forkhead Box O3a (FOXO3a). DSP revealed the downregulation of tumour promoting genes such as chitinase‐like protein 3 (CHIL3/CHI3L3/YM1) and multiple pathways including phosphatidylinositol 3'‐kinase‐Akt (PI3K‐AKT) signalling. The snRNAseq demonstrated a significant loss of cellular clusters in the Sel‐GemPac‐treated mice tumours including the CD44+ stem cell population.
Conclusion
Taken together, these results demonstrate that the Sel‐GemPac treatment caused broad perturbation of PDAC‐supporting signalling networks in the KPC mouse model. Highlights The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac). Exporter protein exportin 1 (XPO1) inhibitor selinexor (Sel) with GemPac synergistically inhibited the growth of LSL‐KrasG12D/+; LSL‐Trp53R172H/+; Pdx1‐Cre (KPC) mouse derived cell line and enhanced the survival of mice. Digital spatial profiling shows that Sel‐GemPac causes broad perturbation of PDAC‐supporting signalling in the KPC model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Detroit Medical Center, Detroit, Michigan, USA.
- UH Seidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.
- Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
- Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Henry Ford Cancer Institute, Detroit, Michigan, USA.
ORCID-Profile: Md Hafiz Uddin
Förderung
- NCI NIH HHS
Zitieren
APA
Uddin, M. H., Al-Hallak, M. N., Khan, H. Y., Aboukameel, A., Li, Y., Bannoura, S. F., Dyson, G., Kim, S., Mzannar, Y., Azar, I., Odisho, T., Mohamed, A., Landesman, Y., Kim, S., Beydoun, R., Mohammad, R. M., Philip, P. A., Shields, A. F., & Azmi, A. S. (2023). Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1513
Vancouver
Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, et al. Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1513
BibTeX
@article{Uddin2023,
author = {Uddin, Md Hafiz and Al-Hallak, Mohammad Najeeb and Khan, Husain Yar and Aboukameel, Amro and Li, Yiwei and Bannoura, Sahar F and Dyson, Gregory and Kim, Seongho and Mzannar, Yosef and Azar, Ibrahim and Odisho, Tanya and Mohamed, Amr and Landesman, Yosef and Kim, Steve and Beydoun, Rafic and Mohammad, Ramzi M and Philip, Philip A and Shields, Anthony F and Azmi, Asfar S},
title = {Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1513}
}
EUVIMED